May 2, 2008: When Merck & Co’s chief executive Richard Clark revealed last week that the US pharma giant is “aggressively looking” for a suitable biotech company to buy, it initially sounded like any number of big pharma CEO interviews in recent months, reassuring shareholders that they are striving to bolster thin pipelines and plug patent expiry holes with the “right” acquisition.